The poster's maximum size is A0 (841 x 1189 mm; width x height).

Correct format...    Wrong format...

Posters with an odd number will be presented during Poster Session 1 (Tuesday, 22 September, 13:15-15:00). Posters with an even number will be presented during Poster Session 2 (Wednesday, 23 September, 13:10-15:10). All posters should stay up for the entire duration of the meeting, independently of the session to which they have been assigned.

P.1 Othmane Adli (Casablanca, Morocco)
Aberrant methylation of IDH3A links epigenetic reprogramming to mitochondrial metabolic dysfunction in prostate cancer

P.2 Anam Aftab (Catanzaro, Italy)
Harnessing BRCA1-mediated nutrient regulation for anticancer therapy in triple-negative breast cancer cells

P.3 Melina Albano (Padua, Italy)
Multi-omic and functional profiling of glucose deprivation resistance in glioblastoma

P.4 Anisa Aliju (Liège, Belgium)
Metabolic control of mRNA translation as a vulnerability in lung cancer

P.5 Beatrice Angi (Padua, Italy)
Cell-specific deletion of Kv1.3 potassium channel modulates regulatory T cell-function within the tumor microenvironment

P.6 Sidra Asghar (Milan, Italy)
eIF6 phosphorylation at the crossroads of translation, metabolism, and stress adaptation

P.7 Martina Avanatti (Pisa, Italy)
Chronic hyperinsulinemia promotes selective adaptive signaling without overt aggressive phenotypes in breast cancer models

P.8 Mayank Bajaj (Hyderabad, India)
Compensatory one-carbon metabolic rewiring defines aggressive subtypes and metabolic dependencies in IDH1-Mutant gliomas

P.9 Saikat Banerjee (Padua, Italy)
Exploring the roles of mitochondria-lysosome contact sites in cellular metabolism

P.10 Francesco Baschieri (Innsbruck, Austria)
Metabolic adaptations of cancer cells during contact guidance migration

P.11 Roberta Basile (Novara, Italy)
From metabolism to immunity: OADHC dictates the tumor microenvironment in LUAD

P.12 Valentina Basso (Padua, Italy)
MIEF1 links mechanotransduction to innate immune activation in tumors

P.13 Giulia Battistello (Padua, Italy)
Elucidating possible resistance mechanisms of the specific mitochondrial Kv1.3 channel inhibitor PAPTP in pancreatic ductal adenocarcinoma cells

P.14 Anna Beielstein (Cologne, Germany)
Pentose phosphate pathway inhibition activates macrophages towards phagocytic lymphoma cell clearance

P.15 Francesca Bianco (Turin, Italy)
ORAI1 inhibition and photodynamic therapy: novel combination therapy for pancreatic ductal adenocarcinoma

P.16 Giulia Elizabeth Borsatti (Rome, Italy)
Metabolic and inflammatory crosstalk in triple-negative breast cancer brain metastasis: the role of IKKβ and arginine metabolism

P.17 Roberta Bortolozzi (Padua, Italy)
Fatty Acid metabolism, a targetable metabolic vulnerability of chemotolerant medulloblastoma cells

P.18 Francesca Bozzetto (Padua, Italy)
GTP homeostasis supports mitochondrial cristae remodeling and pancreatic tumor progression

P.19 Valentina Brillo (Padua, Italy)
A RNAi-based approach to selectively downregulate mitochondrial ion channels in poor prognosis cancers

P.20 Christian Buratto (Padua, Italy)
Beyond Complex I biogenesis: ACAD9 couples fatty-acid metabolism to Complex I conformational plasticity

P.21 Beatrice Calciolari (Padua, Italy)
Lactate-dependent histone acetylation degenerates during B cell aging and lymphomagenesis

P.22 Luca Campea (Rome, Italy)
Metformin inhibits colorectal cancer growth by disrupting lysosome-mitochondria communication through a PEN2-NRF2 signaling module

P.23 Martina Canton (Padua, Italy)
Metabolic adaptation reshapes drug response in pediatric brain tumors

P.24 Veronica Carpanese (Padua, Italy)
Unveiling the molecular mechanisms of K_Ca3.1 in pancreatic cancer development

P.25 Maria Egle Castorina (Padua, Italy)
Investigating the crosstalk between Schwann cells and macrophages in peripheral nerve sheath tumors

P.26 Carel Cherfan (Bordeaux, France)
Decoding the mitochondrial dependency of Sézary cells: a new therapeutic strategy

P.27 Pietro Chiolerio (Padua, Italy)
Human neuromuscular organoids mimic cancer induced muscle cachexia

P.28 Chiara Ciardiello (Naples, Italy)
Beyond the Warburg effect: metabolic diversity in Burkitt lymphoma and HCL-like B-cell neoplasms

P.29 Dulce Ciuffetelli (Flint, MI, USA)
Utilizing three-dimensional (3D) culturing to study the effects of microenvironmental stress on invasiveness of MDA-MB-231 breast cancer cells

P.30 Maiara Caroline Colombera (Turin, Italy)
Investigating the role of PRDX3 in iron metabolism and tumor biology in lung adenocarcinoma

P.31 Carole Dabadie (Lyon, France)
Striated skeletal muscle resistance to metastasis

P.32 Georges Daoud (Beirut, Lebanon)
Assessing the effects of thymoquinone (TQ) alone and in combination with cisplatin (CDDP) on ovarian cancer cells

P.33 Arezoo Darbandi (Padua, Italy)
mTORC1 signaling orchestrates epigenetic reprogramming and survival pathways in adult T-cell leukemia cells

P.34 Giorgia Della Rocca (Rome, Italy)
GPD2 blockade disrupts redox adaptation in colorectal cancer, inducing vulnerability to LDH inhibition and fasting

P.35 Donatella Delle Cave (Naples, Italy)
L1CAM loss fuels pancreatic cancer aggressiveness and fibrosis through lipid metabolic reprogramming

P.36 Christophe Deroanne (Liège, Belgium)
Adamts12, an enzyme at the crossroads of lipid metabolism and tumor progression

P.37 Caterina Dieni (Padua, Italy)
Identification of novel protective pharmacological strategies against chemotherapy-induced neurotoxicity through mitochondrial homeostasis preservation

P.38 Antigoni Diokmetzidou (Padua, Italy)
Metabolite-driven remodeling of mitochondria-ER contact sites in breast cancer progression

P.39 Chiara Donno (Novara, Italy)
EML4-ALK lung cancer triggers systemic energetic collapse and muscle wasting

P.40 Laurine Dupriez (Liège, Belgium)
MAPK-dependent KEAP1 degradation drives redox rewiring and therapeutic vulnerabilities in non-V600 BRAF-mutant lung adenocarcinoma

P.41 Gabriela Dziurman (Krakow, Poland)
Relating tumor oxygenation and redox dynamics to metabolic heterogeneity using EPR imaging

P.42 Nahia Espie Basurco (Pessac, France)
Targeting lipid release by lipases in glioblastoma

P.43 Andrea Evinova (Martin, Slovakia)
Metabolic and mitochondrial responses to ATP-sensitive potassium channel modulation in neuroblastoma cells

P.44 Anais Elisabetta Femia (Turin, Italy)
CRISPR/Cas9 screening in plasmax-grown cancer cells identifies metabolic gene alterations under iron‑modulated conditions

P.45 Federica Ferrarini (Padua, Italy)
Characterization of metabolic heterogeneity in high-grade serous ovarian carcinoma: development and validation of an IHC-based panel

P.46 Alessandra Fiore (Verona, Italy)
Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma

P.47 Carlo Alberto Flora (Padua, Italy)
Dissecting the role of Kv1.3 potassium channel in the cross-talk between melanoma cells and macrophages

P.48 Clémence François (Brussels, Belgium)
Immunospheroids: a 3D framework for the advancement of immunotherapy

P.49 Steffen Frederiksen (Heidelberg, Germany)
The mevalonate pathway enzyme ACAT2 influences hepatocellular carcinoma tumorigenesis

P.50 Alicja Gazda (Kraków, Poland)
RIPK4 regulates cholesterol metabolism and lipid droplet formation in melanoma cells

P.51 Noemi Ghiglione (Turin, Italy)
MLK4 regulates mitochondrial dynamics and metabolic rewiring in pancreatic cancer

P.52 Valentina Giorgio (Bologna, Italy)
The pro-oncogenic role of the endogenous inhibitor of ATP synthase IF₁ in cervix and lung cancers

P.53 Anna Gogna (Brescia, Italy)
Gremlin-1-driven adipocyte reprogramming orchestrates stromal-tumor interactions to support pancreatic cancer progression

P.54 Sijia Guo (Turin, Italy)
IκB/NF-κB supports tumor progression through fatty acid oxidation and CD8+ T-cell impairment

P.55 Kimberley Hanssen (Heidelberg, Germany)
EWSR1::ETS–MYC signalling drives a druggable polyamine dependency in aggressive Ewing sarcoma

P.56 Jozef Hatok (Martin, Slovakia)
Nutritional modulation of epigenetic and lncRNA networks in glioblastoma: Synergistic effect of methionine restriction and sodium butyrate exposition

P.57 Camille Humeau (Pessac, France)
Mitochondrial-associated CB1: a missing piece in glioblastoma therapy?

P.58 Elizabeta Ilieva (Bologna, Italy)
Tumor acidosis reveals a functional coupling between the circadian clock and PERK/ATF6 branches of the unfolded protein response

P.59 Romane Jobé (Liège, Belgium)
Ceramide-dependent biogenesis of adipocyte-derived extracellular vesicles promotes tumor progression

P.60 Sandra Kienast (Zurich, Switzerland)
Polyamines and codon-specific translation regulation in cancer

P.61 Ekaterina Kuznetsova (Clermont-Ferrand, France)
PAXBP1-dependent metabolic rewiring controls proliferation and cisplatin sensitivity in immortalized germ cells

P.62 Lucia La Sala (Naples, Italy)
P2RX4-driven mitochondrial calcium flux regulates lipid metabolism in clear cell renal cell carcinoma

P.63 Martina La Spina (Padua, Italy)
Linking mitochondrial metabolism to extracellular matrix remodeling: a TRAP1-dependent program driving MPNST progression

P.64 Matteo Levorato (Woluwe Saint-Lambert, Belgium)
Arginase 2 activity is a metabolic vulnerability in breast cancer bone metastasis

P.65 Miriam Lisci (Lausanne, Switzerland)
Functional nutrient-genetic profiling reveals biotin and FBXW7 are essential to bypass glutamine addiction

P.66 Pietro Lugato (Padua, Italy)
Translational and metabolic control of targeted therapy resistance in melanoma: primary cilia as a central hub

P.67 Alessia Magro (Padua, Italy)
Loss of GLS1 promotes serine biosynthesis to sustain nucleotide production and proliferation in melanoma cells

P.68 Lorenzo Manfreda (Monza, Italy)
Hypoxia-driven metabolic reprogramming promotes ferroptosis resistance in AML

P.69 Charles Mélotte (Liège, Belgium)
Modulation of the sulfur relay pathway to counteract therapy resistance in luminal breast cancer: a drug design approach

P.70 Furqan Memon (Naples, Italy)
AdipoRon and TGF-β1 modulate EMT and morphological features in A549 lung cancer spheroids: insights into tumor progression

P.71 Vittoria Michelotto (Padua, Italy)
Dissecting the physical and functional interaction between RCC1L and NME4

P.72 Rossella Migliorino (Naples, Italy)
Valproic acid and simvastatin combined with chemotherapy reprogram pancreatic cancer metabolism through microRNA-driven oxidative phosphorylation and glycolysis rewiring

P.73 Giulia Milan (Padua, Italy)
Reprogramming of cholesterol sensing in epithelial cells supports pancreatic inflammation

P.74 Erick Mitchell-Velasquez (Philadephia, PA, USA)
NNMT loss drives prostate cancer progression through epigenetic and metabolic reprogramming

P.75 Orsola Montini (Monza, Italy)
Exploiting microbiota to improve CARCIK cell fitness and metabolism for the treatment of acute myeloid leukemia

P.76 Mahta Moraghebi (Adelaide, Australia)
IDH1 mutation remodels peroxisome biology and peroxisome-dependent metabolic responses in cancer cells

P.77 Roberta Moschini (Pisa, Italy)
Chronic hyperglycemia drives cell-line-specific glucose utilization and drug-response adaptations in NSCLC cells

P.78 Agustina Moyano (Padua, Italy)
Clonal determinants of breast cancer dormancy and recurrence reveal metabolic programs associated with metastatic fitness

P.79 Roberta Noè (Padua, Italy)
Do sweetened beverages increase pancreatic cancer risk? Interrogating nucleolar sensing of fructose-derived acetate

P.80 Jowana Obeid (Stony Brook, NY, USA)
Epigenetic regulation of KLF4 controls metabolic reprogramming of breast cancer cells plasticity responding to acidic tumor microenvironment

P.81 Gergely Pallag (Budapest, Hungary)
Respiratory chain control of choline metabolism in hepatocellular carcinoma

P.82 Carlotta Paoli (Padua, Italy)
Can targeting mitochondrial potassium channels unlock new combination therapies for pancreatic cancer?

P.83 Martina Perin (Turin, Italy)
MALAT-1/C/EBPβ/fatty acid β-oxidation axis: a novel druggable pathway determining resistance to chemotherapy and immune-evasion in non-small cell lung cancer

P.84 Filippo Piccoli (Verona, Italy)
Mutant p53 drives glycolytic rewiring and protein lactylation in pancreatic ductal adenocarcinoma

P.85 Maria Poles (Verona, Italy)
Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells

P.86 Aurelien Pottier (Brussels, Belgium)
Ferroptosis as a therapeutic vulnerability in TP53-mutated acute myeloid leukemia

P.87 Milena Putnik (Padua, Italy)
Linking voltage-gated potassium channels to gene regulation through protein- protein interactions

P.88 Ezzahra Rachid (Settat, Morocco)
Metabolic, oxidative, and autophagic adaptations in imatinib-resistant chronic myeloid leukemia: insights from K562 cell models

P.89 Vittoria Raimondi (Padua, Italy)
Exploiting redox metabolism: a translational strategy to overcome venetoclax resistance in acute myeloid leukemia

P.90 Elena Rainero (Sheffield, United Kingdom)
The extracellular matrix promotes pancreatic cancer cell growth by controlling sugar metabolism

P.91 Ophélie Renoult (Brussels, Belgium)
Persistence of carbonic anhydrase 9 in chemotherapy-tolerant cancer cells: a tool to identify metabolic vulnerabilities and chronotherapeutic strategies

P.92 Michela Rossini (Padua, Italy)
ER-mitochondria contact sites modulate melanoma progression and chemoresistance

P.93 Alessia Ruzza (Padua, Italy)
TG2 orchestrates mitochondrial and lipid metabolism to boost TNBC progression

P.94 Buse Sari (Brussels, Belgium)
Towards metabolic targeting of residual disease in chemotherapy-treated HR+/HER2− breast cancers

P.95 Roberta Sartori (Padua, Italy)
RNA-based multi-target therapy to restore gene networks and prevent cancer-induced cachexia

P.96 Angela Maria Savino (Monza, Italy)
D-2-hydroxyglutarate impairs cancer cell survival rewired through fructose-dependent metabolic reprogramming

P.97 Elena Savio (Turin, Italy)
Tumor microenvironmental acidosis and Ca²⁺ channels interplay in the progression and chemoresistance of PDAC

P.98 Nilde Scalisi (Padua, Italy)
Lactate fuels acetyl-CoA dependent epigenetic remodeling in B cells during germinal center reaction

P.99 Niklas Schött (Cologne, Germany)
Determining the effects of CoA-biosynthesis intermediates on cell function

P.100 Anna Sebestyén (Budapest, Hungary)
Modelling metabolic adaptation and mTOR signalling heterogeneity in 3D bioprinted and tumour-derived cancer tissue structures

P.101 Rocio Seniuk (Houston, TX, USA)
Metabolic drivers of hormone-resistant prostate cancer and their role in bone metastatic progression

P.102 Anna Shevzov-Zebrun (Cambridge, MA, USA)
Glucose limitation following RAS(ON) inhibition creates a metabolic vulnerability under hypoxia in PDAC

P.103 Caroline Shibuya (Barretos, Brazil)
Exploring NOX4-driven metabolic vulnerabilities in melanoma treatment response to immune checkpoint inhibitors

P.104 Alfredo Smiriglia (Florence, Italy)
CYP1A1 regulates estrogen receptor activity and response to CDK4/6 inhibitors in estrogen receptor-positive breast cancer cells

P.105 Francesco Spallotta (Rome, Italy)
P4HA1 drives dysmetabolic PDAC and represents a potential target to improve therapy response

P.106 Sarah Srhir (Woluwe-Saint-Lambert, Belgium)
Therapeutic harnessing of the effects of time-restricted feeding on tumor metabolism

P.107 Anna Sturaro (Padua, Italy)
Targeting Metabolic Plasticity to Overcome Everolimus Resistance in T-ALL

P.108 Vanja Tadic (Milan, Italy)
Nutrient-responsive eIF6 signaling and metabolic adaptation in high-grade serous ovarian cancer

P.109 Luca Matteo Todesca (Padua, Italy)
Understanding the K_v1.3-STAT3 interaction in cancer

P.110 Margherita Toffanin (Padua, Italy)
Taming the metabolism of tumor associated macrophages to fight peripheral nerve sheet tumors

P.111 Chiara Trento (Padua, Italy)
Functional and clinical impact of mitochondrial DNA mutations in ovarian and colorectal cancer

P.112 Eloisa Turco (Padua, Italy)
The role of skeletal muscle peroxisomes in cancer cachexia

P.113 Violaine Vandenhooft (Liège, Belgium)
Mitochondrial OPA1 loss converts extracellular vesicles into inducers of tumor regression

P.114 Tatiana Varanita (Padua, Italy)
Myeloid Kv1.3 loss promotes tumor progression by reshaping the tumor immune microenvironment

P.115 Alice Verdier (Luxembourg, Luxembourg)
Metabolic rewiring of one-carbon related pathways drives chronic lymphocytic leukemia progression

P.116 Federica Vianello (Padua, Italy)
Transglutaminase type 2 regulates metabolism and chemoresistance in melanoma

P.117 Virginia Vigiano Benedetti (Rome, Italy)
Site-specific CpG hypermethylation contributes to breast cancer progression by GLP-1R down-regulation

P.118 Elodie Viry (Luxembourg, Luxembourg)
Therapeutic vulnerabilities and resistance mechanisms to one-carbon metabolism inhibition in B-cell malignancies

P.119 Patrik Vital (Barretos, Brazil)
Tumor grade captures the immunometabolic shift driving TKI resistance to guide sunitinib versus combination therapy in ccRCC

P.120 Zhenyi Wang (Oxford, United Kingdom)
Phenotype-guided protonophore discovery and cubosome delivery in pancreatic cancer

P.121 Annalena Weber (Padua, Italy)
The effect of the mevalonate pathway on the PD-L1/PD-L2 signaling axis in BRAF^mutagainst NRAS^mut melanoma

P.122 Weronika Wilczak (Münster, Germany)
Microenvironmental stress modulates invasion and response to KRAS inhibition in PDAC spheroids